CNR1 Near gene (SNP3)

The Third CNR1 Locus — An Independent Genetic Switch for Substance Dependence

The CNR1 gene encodes
CB1 | Cannabinoid receptor type 1 — the most abundant G-protein-coupled receptor
in the brain, expressed densely in the prefrontal cortex, hippocampus, amygdala, and
basal ganglia. CB1 is the primary target for the brain's own endocannabinoids
(anandamide and 2-AG) and for the psychoactive component of cannabis, THC,
the master regulator of endocannabinoid signaling across the brain's reward and
emotion circuits. Two CNR1 variants — rs806368 and rs1049353 — are already well
characterized as a tight haplotype block that modulates CB1 receptor expression and
shapes vulnerability to cannabis-related brain changes. Rs6454674 tells a different
story: it sits in a completely separate region of the CNR1 gene, captures independent
genetic variation, and exerts its most significant effects not alone, but in combination
with rs806368 — producing synergistic substance dependence risk that neither variant
generates individually.

The Mechanism

Rs6454674 lies within an intron of CNR1 at chromosome 6 position 88,163,211 (GRCh38).
The CNR1 gene is on the minus strand, and the plus-strand alleles — T (reference) and
G (alternate) — are therefore the complement of the coding-strand orientation used in
some older publications. The variant's intronic location means it does not change the
CB1 protein sequence directly. Its functional mechanism remains to be fully
characterized, but the most likely explanation is a regulatory role: intronic variants
can affect mRNA splicing, create or disrupt transcription factor binding sites within
intronic enhancers, or influence alternative transcript production. The CNR1 locus
produces multiple transcript isoforms with distinct functional properties, and
regulatory variants within introns have documented effects on CNR1 expression in
postmortem brain tissue.

Critically, rs6454674 and rs806368 sit in entirely separate
linkage disequilibrium | LD — a statistical term describing the non-random association
of alleles at nearby loci. High LD means the variants are inherited together and tag
the same underlying mutation; low LD means they are inherited independently and
capture distinct genetic signals blocks within the CNR1 region.
Nomura et al. 2009 | Nomura A et al. Interaction between two independent CNR1 variants
increases risk for cocaine dependence in European Americans. Neuropsychopharmacology, 2009
formally measured the LD between them: D' = 0.026, r² = 0. These are the statistics
of complete independence — the two variants are essentially uncorrelated. This
independence is what makes their combination scientifically interesting: two separate
regulatory variants in the same gene, each capturing different aspects of CB1 biology,
produce a synergistic effect on addiction risk that exceeds what either contributes alone.

The Evidence

Drug and alcohol dependence — the original finding. The first evidence for
rs6454674 came from
Zuo et al. 2007 | Zuo L et al. CNR1 variation modulates risk for drug and alcohol
dependence. Biol Psychiatry, 2007,
a study of 1,001 European- and African-American individuals assessed for drug
dependence (DD) and alcohol dependence (AD). The G allele at rs6454674 showed
a dose-response relationship with substance dependence subtypes: risk increased
with each additional copy of the G allele. More strikingly, when the interaction
between rs6454674(G+) and rs806368(T/T) was tested, it produced p = 0.0002 for
drug dependence alone — a near three-order-of-magnitude improvement over either
SNP's individual effect. The combined p-value for comorbid drug and alcohol
dependence was 0.0003; for alcohol dependence alone, 0.007. This interaction
signal was the strongest finding in the entire CNR1 locus scan and established
these two independent regulatory variants as a functionally cooperative pair.

Cocaine dependence — replication and LD confirmation.
Nomura et al. 2009 | Nomura A et al. Interaction between two independent CNR1
variants increases risk for cocaine dependence in European Americans.
Neuropsychopharmacology, 2009
replicated the interaction in four independent cocaine dependence samples:
European-American family-based (p = 0.015), European-American case-control
(p = 0.003), African-American family-based, and African-American case-control.
This study also provided the formal LD measurement (D' = 0.026, r² = 0) between
rs6454674 and rs806368, and described three distinct haplotype blocks across the
45 kb CNR1 region — rs806368 in one block, rs6454674 in a separate block —
confirming that the interaction reflects true genetic independence rather than
statistical noise from correlated alleles.

Cocaine dependence — further replication.
Gelernter et al. 2011 | Gelernter J et al. Further evidence for association
between genetic variants in the cannabinoid receptor 1 (CNR1) gene and cocaine
dependence. Addict Biol, 2011
examined 883 cocaine-dependent cases and 334 controls of African descent.
The GG homozygous genotype at rs6454674 was more common in cocaine-dependent
cases (minor allele frequency 0.13 in cases vs. 0.08 in controls), and in a
recessive model the association reached p = 0.017 independently. When combined
with prior study data in meta-analysis, the G allele reached p = 0.004.

Alcohol dependence haplotypes.
Marcos et al. 2012 | Marcos M et al. Cannabinoid receptor 1 gene is associated
with alcohol dependence. Alcohol Clin Exp Res, 2012
in 298 male alcoholics found that a GGT haplotype spanning rs6454674(G),
rs1049353(G), and rs806368(T) was significantly overrepresented in
alcohol-dependent individuals (p = 0.006), and that the rs6454674 G allele
interacted with the rs806368 C allele at p = 0.009.

Schizophrenia symptom severity. A Turkish study (Copoglu et al. 2015, n = 66
patients, 65 controls; published in Klinik Psikofarmakol Bülteni — not PMID-indexed)
found no difference in rs6454674 allele frequencies between schizophrenia patients
and healthy controls, but found that patients carrying the G allele at rs6454674
had significantly lower PANSS total, PANSS positive, PANSS negative, PANSS general
psychopathology, and CGI-S scores than patients without the polymorphism. This
observation — the G allele conferring both increased substance dependence risk and
attenuated schizophrenia severity — is biologically intriguing but based on a
small sample from a single center and should be considered emerging evidence only.
The endocannabinoid system is known to participate in both domains, and altered
CB1 expression or signaling could plausibly affect psychotic symptom expression
independently of susceptibility.

Practical Implications

Rs6454674's primary clinical relevance is as an independent contributor to the
endocannabinoid genetic risk architecture for substance dependence. At ~10% GG
frequency globally, a meaningful fraction of the population carries two copies of
the risk allele. The interaction data place this variant's importance in context:
carrying both the rs6454674 G allele and the rs806368 TT genotype — which occur
together in approximately 6–8% of Europeans and African Americans — produces the
highest documented CNR1 genetic risk for drug dependence.

Because rs6454674 captures variation in a completely different regulatory region
of CNR1 from the rs806368/rs1049353 haplotype, it provides genuinely additive
information. Testing rs6454674 alongside the established haplotype block gives a
more complete picture of the CNR1 risk architecture than either marker set alone.

Interactions

Rs6454674 and rs806368 are the two CNR1 variants with the strongest documented
gene-gene interaction for substance dependence (Zuo 2007; Nomura 2009). Their
independence is proven: D' = 0.026, r² = 0. The rs806368/rs1049353 haplotype
block (D' = 0.95 between those two) represents one molecular signal; rs6454674
represents a second, independent signal from a different part of the same gene.
Combined carriers of rs6454674(G+) and rs806368(TT) face the steepest CNR1
genetic slope toward drug and alcohol dependence documented in the literature.
See also: the FAAH gene (rs324420), which controls anandamide breakdown and
has been studied for interactive effects with CNR1 variants in cannabis cue
reactivity and stress-response contexts.